NICE Recommends Mavenclad (Cladribine Tablets) for Highly Active Multiple Sclerosis
<ul>
<li>First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe</li>
<li>Mavenclad has shown sustained clinical efficacy up to four years with a maximum of 20 days of oral treatment over two years</li>
</ul>
<li>First multiple sclerosis (MS) therapy to achieve positive NICE recommendation in the shortest possible timeframe</li>
<li>Mavenclad has shown sustained clinical efficacy up to four years with a maximum of 20 days of oral treatment over two years</li>
</ul>
- 10.11.2017, 10:32
- Kategoria: Zdrowie i styl życia
- Źródło: PR Newswire